Lumexa Imaging (NASDAQ:LMRI – Get Free Report) had its target price upped by investment analysts at Barclays from $13.00 to $17.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 13.17% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. KeyCorp assumed coverage on shares of Lumexa Imaging in a research report on Thursday, September 24th. They issued an “overweight” rating and a $18.00 target price for the company. Raymond James Financial set a $19.00 target price on shares of Lumexa Imaging and gave the stock a “strong-buy” rating in a research note on Wednesday, November 11th. Weiss Ratings downgraded Lumexa Imaging from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday. Truist Financial initiated coverage on shares of Lumexa Imaging in a research note on Monday, October 5th. They set a “buy” rating and a $18.00 price target on the stock. Finally, Wall Street Zen raised Lumexa Imaging from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $17.60.
View Our Latest Stock Analysis on LMRI
Lumexa Imaging Price Performance
Shares of NASDAQ:LMRI opened at $15.02 on Tuesday. The company’s 50 day moving average is $11.50 and its 200 day moving average is $11.09. The company has a market cap of $1.44 billion and a PE ratio of -27.81. Lumexa Imaging has a twelve month low of $6.45 and a twelve month high of $19.45. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 1.40.
Lumexa Imaging (NASDAQ:LMRI – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.19. Lumexa Imaging had a negative return on equity of 2.93% and a negative net margin of 1.96%. The firm had revenue of $271.97 million for the quarter. On average, sell-side analysts forecast that Lumexa Imaging will post 0.22 EPS for the current year.
Institutional Trading of Lumexa Imaging
Institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC acquired a new stake in shares of Lumexa Imaging in the second quarter worth $24,269,000. Brooklands Fund Management Ltd acquired a new stake in shares of Lumexa Imaging during the 3rd quarter valued at approximately $21,577,000. BlackRock Inc. acquired a new position in Lumexa Imaging in the second quarter valued at approximately $15,771,000. Brigade Capital Management LP bought a new position in shares of Lumexa Imaging during the second quarter worth about $7,511,000. Finally, First Eagle Investment Management LLC acquired a new stake in Lumexa Imaging in the 3rd quarter valued at approximately $4,753,000.
About Lumexa Imaging
Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.
Further Reading
- Five stocks we like better than Lumexa Imaging
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Lumexa Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumexa Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
